4-(6,8-DIBROMO-4-OXO-1,2,3,4-TETRAHYDROQUINOLIN-2-YL)BENZONITRILE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	PSSXEFIBECIPRW-UHFFFAOYSA-N
Smiles	Brc1cc(Br)c2NC(CC(=O)c2c1)c3ccc(cc3)C#N
InChI	InChI=1S/C16H10Br2N2O/c17-11-5-12-15(21)7-14(20-16(12)13(18)6-11)10-3-1-9(8-19)2-4-10/h1-6,14,20H,7H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H10Br2N2O
Molecular Weight	406.07
AlogP	4.3
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	1.0
Polar Surface Area	52.89
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	21.0

Assay Description	Organism	Bioactivity
Growth inhibition of Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay	Homo sapiens	100.0 nM
Growth inhibition of Homo sapiens (human) MCF-7 cells assessed as cell growth at 10 '-4 M after 48 hr by SRB assay	Homo sapiens	-58.5 %
Growth inhibition of Homo sapiens (human) MCF-7 cells assessed as cell growth at 10 '-5 M after 48 hr by SRB assay	Homo sapiens	-5.1 %
Growth inhibition of Homo sapiens (human) MCF-7 cells assessed as cell growth at 10 '-6 M after 48 hr by SRB assay	Homo sapiens	8.2 %
Growth inhibition of Homo sapiens (human) MCF-7 cells assessed as cell growth at 10 '-7 M after 48 hr by SRB assay	Homo sapiens	43.1 %
Cytotoxicity against Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay	Homo sapiens	100000.0 nM
Growth inhibition of Homo sapiens (human) MCF-7 cells assessed as total cell growth after 48 hr by SRB assay	Homo sapiens	0.126 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2237855
PubChem	66561248

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).